-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
OSS-128167
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/887686-02-4.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 887686-02-4 |
| Description | OSS-128167 is a selective SIRT6 inhibitor (IC50 = 89 µM). |
Product Information
| Synonyms | OSS-128167; OSS 128167; OSS128167; SIRT6-IN-1; STK292625; STK 292625; STK-292625; 5-[3-(furan-2-amido)benzamido]-2-hydroxybenzoic acid; 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid |
| Molecular Weight | 366.32 |
| Molecular Formula | C19H14N2O6 |
| Canonical SMILES | C1=CC(=CC(=C1)NC(=O)C2=CC=CO2)C(=O)NC3=CC(=C(C=C3)O)C(=O)O |
| InChI | InChI=1S/C19H14N2O6/c22-15-7-6-13(10-14(15)19(25)26)20-17(23)11-3-1-4-12(9-11)21-18(24)16-5-2-8-27-16/h1-10,22H,(H,20,23)(H,21,24)(H,25,26) |
| InChIKey | HTJWLEGCECXGSQ-UHFFFAOYSA-N |
| Purity | 99% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to light yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 568 |
| Exact Mass | 366.08518617 |
| In Vitro | OSS_128167 is a selective SIRT6 inhibitor with IC50s of 89, 1578 and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 inhibits SIRT6 in the micromolar range, but shows promising selectivity, since its IC50 value for SIRT6 is approximately 17 times lower compare to the IC50 for SIRT1 and 9 times lower compare to SIRT2. OSS_128167 (200 μM) induces chemosensitization in primary multiple myeloma (MM) cells (NCI-H929), as well as in melphalan-resistant (LR-5) and doxorubicin-resistant (Dox40) MM cell lines. |
| Target | SIRT6:89 μM (IC50) SIRT2:751 μM (IC50) SIRT1:1578 μM (IC50) |
| XLogP3-AA | 2.7 |
